Pulse Biosciences, Inc. PLSE Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

Boston ScientificBSX

$81M-29.6%

Celldex TherapeuticsCLDX

——

Kymera TherapeuticsKYMR

——

IncyteINCY

——

Other financials

Income statement

See full

Revenue$401.0K—

Gross profit$31.0K—

Operating income-$19.2M-6.1%

Net income-$18.6M-10.6%

EPS (diluted)-$0.49-2.1%

Balance sheet

See full

Cash & equivalents$68.3M-42.7%

Total debt$7.2M-16.6%

Total equity$66.3M-44.0%

Total assets$81.6M-38.8%

Cash flow

See full

Operating cash flow-$14.6M-7.9%

CapEx$33.0K-26.7%

Free cash flow-$14.6M-7.8%

Valuation

See full

Market cap$1.77B+38.4%

Profitability

See full

Gross margin-4,067.5%—

Operating margin-10,392.1%—

Net margin-9,929%—

FCF margin-7,390%—

Returns & leverage

See full

Return on equity-80.7%+3.1pp

Debt / equity0.1×0.0×

Current ratio7.3×-8.3×

Where this comes from

Reported directly by Pulse Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Pulse Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulse Biosciences, Inc.'s proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pulse Biosciences, Inc.'s proceeds from issuance of common stock relating to employee stock plans?: Pulse Biosciences, Inc. (PLSE) reported proceeds from issuance of common stock relating to employee stock plans of $465K in Q1 2026.
How has Pulse Biosciences, Inc.'s proceeds from issuance of common stock relating to employee stock plans changed year-over-year?: Pulse Biosciences, Inc.'s proceeds from issuance of common stock relating to employee stock plans increased by 32.1% year-over-year, from $352K to $465K.